Agency Forms Undergoing Paperwork Reduction Act Review
| Published date | 02 July 2021 |
| Citation | 86 FR 35292 |
| Record Number | 2021-14226 |
| Section | Notices |
| Court | Centers For Disease Control And Prevention,Health And Human Services Department |
Federal Register, Volume 86 Issue 125 (Friday, July 2, 2021)
[Federal Register Volume 86, Number 125 (Friday, July 2, 2021)]
[Notices]
[Pages 35292-35294]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-14226]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-21-0307]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``Gonococcal Isolate Surveillance Project
(GISP)'' to the Office of Management and Budget (OMB) for review and
approval. CDC previously published a ``Proposed Data Collection
Submitted for Public Comment and Recommendations'' notice on March 8,
2021 to obtain comments from the public and affected agencies. CDC did
not receive comments related to the previous notice. This notice serves
to allow an additional 30 days for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Gonococcal Isolate Surveillance Project--Revision--National Center
for HIV/AIDS, Viral Hepatitis, STD, TB Prevention (NCHHSTP), Centers
for Disease Control and Prevention (CDC).
Background and Brief Description
The Gonococcal Isolate Surveillance Project (GISP) was created in
1986 to monitor trends in antimicrobial susceptibilities of Neisseria
gonorrhoeae strains in the United States. GISP continues to be a
collaboration between different branches of the CDC's Division of STD
Prevention, selected regional laboratories, and selected state/local
public health departments and their associated STD specialty care
clinics in the United States. National organizations, local
jurisdictions and individuals use data collected in GISP to understand,
monitor, and prevent further transmission of antibiotic resistant
strains of N. gonorrhoeae. Data from GISP are used to establish a
scientific basis for the selection of gonococcal therapies and to allow
pro-active changes to treatment guidelines before widespread resistance
and failures of treatment occur. To increase capacity to detect and
monitor resistant gonorrhea and to improve the specificity of GISP,
this revision is being submitted to include collection of remnant
nucleic acid amplification test (NAAT)
[[Page 35293]]
specimens and updated data element options for treatment received based
on the 2020 updated gonorrhea treatment recommendations.
GISP core surveillance activities sample
